The observation that silencing ARID1A sensitized cellsto ATRi was particularly interesting as ARID1A is recurrently mutated in a variety of tumour types (45% ovarian clear cell carcinoma (OCCC), 14–19% gastric, bladder and hepatocellular tumours and 2–3% breast tumours17). Here, ARID1A is linked to ovarian clear cell cancer.